IndraLab
Statements
sparser
"To delineate the structural basis of the auto-inhibition of Uch37 and its activation by Rpn13C, we used a Uch37 dimer model derived from its crystal structure and compared it with the structure of the binary complex of ubiquitin-bound Uch37 (PDB ID 4IG7) and its homolog UCH-L3 (PDB ID 1XD3)."
sparser
"The FRF hairpin inserts into the pocket of Uch37 that normally binds ubiquitin, and is clasped in place by binding of the long, C-terminal helix of NFRKB DEU to the catalytic domain of Uch37, which forces the second helix in the Uch37 ULD domain to bend [ xref , xref , xref ] ( xref )."
sparser
"It is also a reversible non‐selective competitive inhibitor of USP14, targeting the formation of Ub‐USP14 or Ub‐UCHL5 conjugates. xref This is achieved by inhibiting the enzymatic activity of USP14 and UCHL5, and VLX1570 shows significant anti‐cancer impact in multiple myeloma and Waldenstrom's macroglobulinemia. xref Anchored in these findings, a phase 1/2 trial evaluating the efficacy and tolerability of VLX1570 in patients with relapsed or refractory multiple myeloma is currently under way (NCT02372240). xref "
sparser
"Undoubtedly, DUB activity is a promising strategy for cancer therapy. xref VLX1570 targets the Ub‐USP14 or Ub‐UCHL5 conjugates and is a reversible non‐selective competitive inhibitor of ubiquitin peptidase 14 (USP14) and ubiquitin carboxyl‐terminal hydrolase 5 (UCHL5) in multiple myeloma. xref VLX1570 has been shown to have significant anti‐cancer efficacy with high potency and solubility."